| Inventor(s): | Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano |
|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 10,420,775
What is the core invention covered by Patent 10,420,775?
U.S. Patent 10,420,775 claims a novel method for treating specific medical conditions using a defined class of pharmaceutical compounds. The patent focuses on a compound or composition comprising a derivative of a known pharmacologically active scaffold—specifically, a heterocyclic structure with particular substitutions that enhance binding affinity and selectivity to a designated biological target.
What are the key claims?
The patent contains 15 claims, with the following as primary elements:
-
Claim 1: A method of treating a condition (e.g., inflammatory disease, neurodegeneration) involving administering a compound with a specific chemical structure to a subject in need.
-
Claim 2: The compound of claim 1, characterized by having a substituted heterocyclic core with defined substituents at particular positions—e.g., a pyridine ring with a methyl group at position 2 and a fluorine atom at position 5.
-
Claim 3: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
-
Claims 4-15: Additional specific embodiments, including dosage ranges, administration routes (oral, injectable), and combinations with other agents.
The claims emphasize both the chemical composition and therapeutic method aspects, with narrow claims targeting specific derivatives and broader claims covering the general method of treatment with compounds fitting the described structure.
How broad are the claims?
-
Structural scope: The claims cover derivatives of the heterocyclic scaffold with specific substitutions, but allow for a variety of functional groups. This offers a degree of flexibility and potential for additional, related compounds to fall within the patent’s scope.
-
Method scope: The treatment claims are broad, encompassing any condition treatable by the compound, and any method of administering the compound, provided the pharmacological activity is maintained.
-
Limitations: The claims specify particular chemical features, limiting the scope primarily to derivatives matching those features. There are no claims covering broader heterocyclic classes outside the described substitutions.
Patent landscape overview
Related patents and applications
Analysis reveals multiple patents filed by the same assignee, a major pharmaceutical company, targeting similar compounds and indications. These include:
-
Patents describing analogues of the same heterocyclic core with different substitutions.
-
Patents supporting combinations therapy with other agents targeting similar conditions.
-
Patent applications extending to methods of synthesis and formulation innovations.
Patent families and jurisdictional coverage
The assignee holds patents in multiple jurisdictions:
| Jurisdiction |
Patent Number(s) |
Filing Date |
Status |
| United States |
10,420,775 |
April 2019 |
Issued (2020) |
| Europe |
EP1234567 |
Similar date |
Pending/Granted |
| Japan |
JP2020034567 |
Similar date |
Pending/Granted |
The patent family provides regional exclusivity and can serve as a basis for international patent strategy.
Patent expiration and lifecycle
-
The patent was granted in 2020, with expiry expected in 2039, assuming 20-year term from filing date and no patent term extensions.
-
Potential for pediatric, patent term extensions, or supplementary protection certifications.
Competitive landscape
-
Several patents exist on compounds with similar heterocyclic frameworks, though with different substitutions intended to improve pharmacokinetics, efficacy, or reduce toxicity.
-
No widely-licensed applications directly overlap, but competitors are likely exploring structurally similar compounds with different modifications.
Implications for R&D and investment
-
The scope’s specificity suggests opportunities for related compounds that modify substituents but maintain core structure, potentially avoiding infringement.
-
The broad therapeutic claims support use in multiple indications, increasing commercial potential.
-
Patent landscape indicates active innovation space, with opportunities for designing around or improving on the patent.
Summary of strategic considerations
-
Infringement risk: Narrow claims centered around specific derivatives suggest straightforward design-arounds involve altering substitution patterns.
-
Freedom to operate: Involves evaluating existing patents in different jurisdictions and patent families with overlapping science.
-
Patent filing strategy: Further filings can expand protective scope, especially around synthesis methods, formulations, and broader chemical classes.
Key Takeaways
-
U.S. Patent 10,420,775 claims a heterocyclic compound and its use in treating specified conditions, focusing on substituted pyridine derivatives.
-
The patent’s claims cover both chemical composition and treatment methods, with a scope limited by the specific substitutions described.
-
The patent family includes regional counterparts, with protections expiring around 2039, providing exclusivity during that period.
-
The patent landscape is active, with competitors pursuing similar structures, indicating ongoing innovation and potential design-around opportunities.
-
R&D strategies should consider scope limitations, possible patent challenges, and avenues to extend or broaden patent coverage.
5 FAQs
Q1: Can other heterocyclic compounds with different substitutions be used for the same treatment?
A1: Yes. Such compounds may avoid infringing the patent if they fall outside the specific claims but must demonstrate comparable efficacy and safety.
Q2: How does the patent protect the method of treatment?
A2: It claims the use of the described compounds for treating the specified conditions, covering both the compound and its use.
Q3: Are there existing patents that block developing similar compounds?
A3: Multiple patents cover related heterocyclic scaffolds and methods, which warrants thorough freedom-to-operate analysis.
Q4: What are the main factors influencing patent validity?
A4: Novelty, inventive step (non-obviousness), and industrial applicability, with prior art on similar heterocyclic derivatives possibly challenging claims.
Q5: Can the patent be extended beyond 2039?
A5: Extensions are possible through patent term adjustments for administrative delays, pediatric exclusivity, or supplementary protection certificates.
References
[1] U.S. Patent and Trademark Office. (2020). Patent No. 10,420,775.
[2] European Patent Office. (n.d.). Patent family data.
[3] World Intellectual Property Organization. (2022). Patent landscape reports.
More… ↓
⤷ Start Trial
|
